Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.37 |
| ▸ | HINT1 | P49773 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16144363 | 0.92 | HPGD (0.41) | HPGDADORA3IMPDH2IMPDH1NT5E | |
| SCHEMBL15070280 | 0.88 | HPGD (0.44) | HPGDADORA3IMPDH2IMPDH1NT5E | |
| SCHEMBL16144340 | 0.88 | ADORA3 (0.53) | ADORA3NT5ESTING1HINT1PDE3B | |
| SCHEMBL15070267 | 0.88 | HPGD (0.44) | HPGDADORA3IMPDH2IMPDH1NT5E | |
| SCHEMBL15070820 | 0.86 | HPGD (0.42) | HPGDADORA3IMPDH2IMPDH1NT5E | |
| SCHEMBL15070263 | 0.85 | HPGD (0.42) | HPGDADORA3IMPDH2IMPDH1NT5E | |
| SCHEMBL15070302 | 0.85 | HPGD (0.44) | HPGDADORA3IMPDH2IMPDH1NT5E | |
| SCHEMBL16375326 | 0.85 | ADORA3 (0.42) | HPGDADORA3NT5ESTING1HINT1 | |
| SCHEMBL15070825 | 0.84 | HPGD (0.41) | HPGDADORA3IMPDH2IMPDH1STING1 | |
| SCHEMBL15070301 | 0.84 | HPGD (0.41) | HPGDADORA3IMPDH2IMPDH1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, SLC28A1, SLC10A1 | HPGD 3613/4885ADORA3 179/4885IMPDH2 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.